Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies

被引：0
|
作者：
Gandhi, L. [1 ]
Gadgeel, S. [2 ]
Shaw, A. [3 ]
Barlesi, F. [4 ]
Crino, L. [5 ]
Yang, J. C-H. [6 ,7 ]
Dingemans, A-M. C. [8 ]
Kim, D-W. [9 ]
de Marinis, F. [10 ]
Schulz, M. [11 ]
Liu, S. [11 ]
Fish, S. [11 ]
Kotb, A. [12 ]
Ou, S-H. I. [13 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[2] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France
[5] Santa Maria della Misericordia Hosp, Med Oncol, Perugia, Italy
[6] Natl Taiwan Univ Hosp, Grad Inst Oncol, Taipei, Taiwan
[7] Natl Taiwan Univ Hosp, Canc Res Ctr, Taipei, Taiwan
[8] MUMC, Pulmonol, Maastricht, Netherlands
[9] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea
[10] European Inst Oncol, Thorac Inst Oncol, Milan, Italy
[11] Genentech Inc, US Med Affairs, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
[12] F Hoffmann La Roche Ltd, Med Affairs, Basel, Switzerland
[13] Univ Calif Irvine, Med Oncol, Orange, CA 92668 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1209PD
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial
    Lee, D. H.
    Kim, D-W.
    Camidge, D. R.
    Langer, C. J.
    Huber, R. M.
    Tiseo, M.
    West, H. L.
    Groen, H. J. M.
    Reckamp, K. L.
    Hochmair, M. J.
    Leighl, N. B.
    Hansen, K. H.
    Gettinger, S. N.
    Paz-Ares, L.
    Kim, E. S.
    Smit, E. F.
    Kim, S-W.
    Ni, Q.
    Zhang, P.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2019, 30 : 634 - +
  • [42] Randomized phase III study of recombinant human Apo-2 ligand (Apo-2 Ligand) plus vinorelbine/cisplatin (NP) verus placebo plus NP in patients with stage IIIB/IV non-small cell lung cancer (NSCLC): A single center report.
    Yu, Lanfang
    Shen, Pang
    Huang, Sui
    Chen, Jing
    Shi, Genming
    Deng, Jing
    Wang, Xiaoting
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) metastatic to the brain
    Chow, L. Q.
    Barlesi, F.
    Bertino, E. M.
    van den Bent, M. J.
    Wakelee, H.
    Wen, P. Y.
    Chiu, C-H.
    Orlov, S.
    Majem, M.
    Chiari, R.
    McKeage, M.
    Yu, C-J.
    Hurtado, F. K.
    Arratia, P. Cazorla
    Song, Y.
    Branle, F.
    Shi, M.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2019, 30 : 602 - 603
  • [44] Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
    Horn, L.
    Wakelee, H.
    Blumenschein, G.
    Reckamp, K.
    Waqar, S.
    Carter, C. A.
    Gitlitz, B. J.
    Infante, J. R.
    Sanborn, R. E.
    Neal, J.
    Gockerman, J. P.
    Dukart, G.
    Harrow, K.
    Liang, C.
    Gibbons, J. J.
    Hernandez, J.
    Newman-Eerkes, T.
    Lim, L.
    Lovly, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Longitudinal circulating tumor DNA (ctDNA) analysis predicts response and reveals the resistance mechanisms of ensartinib in ALK plus NSCLC patients (pts) progressed on crizotinib: Updated analysis of a phase II clinical trial
    Yang, Yunpeng
    Huang, Jie
    Wang, Tao
    Zhou, Jianya
    Zheng, Jing
    Feng, Jifeng
    Zhuang, Wu
    Chen, Jianhua
    Zhao, Jun
    Zhong, Wei
    Zhao, Yanqiu
    Zhang, Yiping
    Song, Yong
    Hu, Yi
    Yu, Zhuang
    Gong, Youling
    Chen, Yuan
    Ye, Feng
    Zhang, Shucai
    Cao, Lejie
    Fan, Yun
    Wu, Gang
    Guo, Yubiao
    Zhou, Chengzhi
    Ma, Kewei
    Fang, Jian
    Feng, Weineng
    Liu, Yunpeng
    Zheng, Zhendong
    Li, Gaofeng
    Wu, Ning
    Song, Wei
    Liu, Xiaoqing
    Zhao, Shijun
    Ding, Lieming
    Mao, Li
    Selvaggi, Giovanni
    Zhu, Larry
    Xiao, Shanshan
    Zhang, Li
    CANCER RESEARCH, 2020, 80 (16)
  • [46] Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naive NSCLC: Initial results from the ALK plus cohort
    Gadgeel, S. M.
    Mok, T. S. K.
    Peters, S.
    Alexander, J. A. A.
    Leighl, N. B.
    Sriuranpong, V.
    Perol, M.
    De Castro, G., Jr.
    Nadal, E.
    De Marinis, F.
    Han, J-Y.
    Yan, M.
    Riehl, T.
    Schleifman, E.
    Paul, S. M.
    Mocci, S.
    Shames, D.
    Mathisen, M. S.
    Dziadziuszko, R.
    ANNALS OF ONCOLOGY, 2019, 30 : 918 - 918
  • [47] ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB IIIA anaplastic lymphoma kinase-positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Solomon, Benjamin J.
    Ahn, Jin Seok
    Barlesi, Fabrice
    Dziadziuszko, Rafal
    Nishio, Makoto
    Shaw, Alice Tsang
    Bordogna, Walter
    Meyenberg, Christoph
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Efficacy and safety of lorlatinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study
    Shaw, Alice Tsang
    Ou, Sai-Hong Ignatius
    Felip, Enriqueta
    Bauer, Todd Michael
    Besse, Benjamin
    Gadgeel, Shirish M.
    Camidge, D. Ross
    Lin, Chia-Chi
    Seto, Takashi
    Soo, Ross A.
    Chiari, Rita
    James, Leonard P.
    Clancy, Jill S.
    Martini, Jean-Francois
    Abbattista, Antonello
    Pithavala, Yazdi K.
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] A phase II single-arm study of LDK378 in patients with ALK-activated (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).
    Shaw, Alice Tsang
    Mok, Tony
    Spigel, David R.
    Nishio, Makoto
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Garcia-Campelo, M. Rosario
    Gruen, Harry J. M.
    Dakhil, Shaker R.
    Schaefer, Eric Scott
    Farrell, Nicholas John
    Blakesley, Rick E.
    Weir, Alexander
    Ristic, Mirta
    Selvaggi, Giovanni
    Scagliotti, Giorgio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Felip, E.
    Carcereny, E.
    Barlesi, F.
    Gandhi, L.
    Sequist, L. V.
    Kim, S-W.
    Groen, H. J. M.
    Besse, B.
    Kim, D-W.
    Smit, E.
    Akimov, M.
    Avsar, E.
    Bailey, S.
    Ofosu-Appiah, W.
    Garon, E. B.
    ANNALS OF ONCOLOGY, 2012, 23 : 152 - 152
12345